Press Release

Bulimia Nervosa Drug Market is Projected to Register a Healthy CAGR by the Forecast to 2026 with top Key players Stryker, Penumbra, Baxter, Novo Nordisk, Abbott, Pfizer

Bulimia nervosa is a psychological eating disorder characterized by binge eating habit and followed by purging. Patient suffering from bulimia nervosa have regular episodes of binge eating which involves eating large amount of food in a shorter duration of time than a normal person and this is followed by attempt to avoid weight gaining by purging what was consumed by the person by self-induced vomiting, excessive usage of medications such as laxatives and diuretics, excessive fasting, excessive exercise. This type of psychological behavior of binge eating and purging affects the physical and mental well-being of the person. It causes chemical imbalances in the body, damage to the digestive system and heart problems.

Global Bulimia Nervosa Drug Market is expected to grow at a steady CAGR of 4.7% in the forecast period of 2019-2026.

Influencing players of this market are: Stryker, Sumitomo Dainippon Pharma, Siemens Healthcare Private, Penumbra, Bristol-Myers Squibb Company, ALLERGAN, AbbVie Inc, Johnson & Johnson Services, Inc, OPIANT PHARMACEUTICALS, Takeda Pharmaceutical Company, Baxter, Merck & Co., Inc, Novo Nordisk A/S, GlaxoSmithKline plc, F. Hoffmann-La Roche, Eli Lilly and Company, Abbott, Pfizer, Novartis AG, Medtronic and others.

FREE | Get Exclusive Sample Report: @

The Bulimia Nervosa Drug market research report contains latest data related to Bulimia Nervosa Drug market with which organizations can get inside-out investigation of industry and future patterns. There is significant knowledge about new product launch, developments, understandings, mergers, partnership, joint endeavors, acquisitions, and others that help to expand their impressions in the industry. The report contains wide knowledge about Bulimia Nervosa Drug market, which will assist the client with discovering the forthcoming snags and guess precise operations. The improvement rate is estimated through this profound and significant study that offers dependable information on the worldwide Bulimia Nervosa Drug market.

20% Extra Discount on this Report @ [email protected]

Market Drivers

  • Increasing prevalence of disorders such as diabetes, cardiovascular diseases and psychic diseases acts as a driver for this market
  • Changing lifestyle and unrealistic body type expectations also drives the market growth
  • Increased peer pressure coupled with the rise in alcoholism also acts as a driver for this market
  • Development in the healthcare expenditure and the government support for the research & development for new and better treatment have fueled the market growth

Market Restraints

  • High cost of therapy is hampering the growth of the market
  • Lack of drugs specific to the treatment of bulimia nervosa can restrict the market growth
  • Lack of awareness amongst people about this disorder can also hamper the market growth

Table of Content:

Part 01: Executive Summary

Part 02: Scope of The Report

Part 03: Global Bulimia Nervosa Drug Market Landscape

Part 04: Global Bulimia Nervosa Drug Market Sizing

Part 05: Global Bulimia Nervosa Drug Market Segmentation by Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers and Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

And More…. Get Detailed TOC @

Segmentation: Bulimia Nervosa Drug Market

By Type (Purging Type, Non-Purging Type),

By Mechanism of Action (Antipsychotics, Antidepressants, Monoamine Oxidase Inhibitors),

By Drug Type (Prozac, Zoloft, Celexa, Lexapro and Wellbutrin),

By Therapy Type (Cognitive Behavioral Therapy, Interpersonal Psychotherapy),

By Treatment (Medications, Psychotherapy, Nutritional counseling),

By Route of Administration (Oral, Intravenous and Others),

By End- Users (Hospitals, Homecare, Specialty Clinics, Others),

By Geography (North America, Europe, South America, Asia-Pacific, Middle East and Africa)

Key Developments in the Market:

  • In June 2019, Sunovion Pharmaceuticals Inc is developing dasotraline drug which is under phase lll of clinical trial for the treatment of binge eating disorder. Dasotraline is a new chemical entity that acts as a dual dopamine and norepinephrine reuptake inhibitor (DNRI). This drug will help in the treatment of eating disorders, ADHD symptoms and behaviors including attention and hyperactivity, in children aged 6-12 years

Competitive Analysis:

Global bulimia nervosa drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of bulimia nervosa drug market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.


Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: [email protected]